Pfizer's integrin αvβ6-targeting Antibody-Drug Conjugate (ADC) candidate, Sigvotatug Vedotin (PF-08046047, also known as SGN-B6A), has progressed to Phase III clinical trials for PD-L1 high-expressing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback